continued from above:
Frunevetmab, the active ingredient in Solensia, is a cat-specific monoclonal antibody (a type of protein) designed to recognize and attach to a protein called nerve growth factor (NGF) that is involved in the regulation of pain. When frunevetmab binds to NGF, it prevents the pain signal from reaching the brain.
So it does not handle OA the same way as Zilosul, which heals and not stop letting the brain know somethings wrong.
(Honestly, why time the editing function on this site by 3 minutes?)
PAR General discussion, page-225
-
- There are more pages in this discussion • 115 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.0¢ |
Change
-0.020(8.00%) |
Mkt cap ! $80.45M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.0¢ | 23.0¢ | $235.8K | 980.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 100000 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 6521 | 2 |
View Market Depth
| Last trade - 16.10pm 05/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |